Compounds > ar 9281
Page last updated: 2024-11-12

ar 9281

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID12000797
CHEMBL ID436774
SCHEMBL ID654229
SCHEMBL ID18464997
MeSH IDM0557147

Synonyms (40)

Synonym
n-(1-acetylpiperidin-4-yl)-n''-(adamant-1-yl)urea
n-(1-acetyl-piperidin-4-yl)-n''-(adamantan-1-yl)urea
bdbm50191854
CHEMBL436774 ,
ar9281
bdbm100423
us8501783, 1153
1-[(1-acetylpiperidin-4-yl)-3-adamantan-1-yl]urea
SCHEMBL654229
n-(1-acetylpiperidin-4-yl)-n'-(adamant-1-yl) urea
HUDQLWBKJOMXSZ-UHFFFAOYSA-N
J3.137.087F ,
1-(adamantane-1-yl)-3-(1-acetylpiperidine-4-yl)urea
apau
4-piperidinamine, 1-acetyl-n-((tricycle(3.3.1.13,7)dec-1-ylamino)carbonyl)-
urea, n-(1-acetyl-4-piperidinyl)-n'-tricyclo(3.3.1.13,7)dec-1-yl-
ar-9281
4HA03Q8EZ9 ,
apau (enzyme inhibitor)
913548-29-5
unii-4ha03q8ez9
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea
SCHEMBL18464997
AKOS030231617
1-(adamant-1-yl)-3-(1-acetylpiperidin-4-yl) urea
DB06345
HY-111151
CS-0034433
Q27259593
D87139
MS-24725
apauapau
1-(1-acetylpiperidin-4-yl)-3-(1-adamantyl)urea
EN300-20353710
3-(1-acetylpiperidin-4-yl)-1-[(3r,5s,7s)-adamantan-1-yl]urea
GLXC-26384
3-(1-acetylpiperidin-4-yl)-1-[(3r,5r)-adamantan-1-yl]urea
EN300-27126239
EN300-1700040
3-(1-acetylpiperidin-4-yl)-1-(adamantan-1-yl)urea

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"0 nM) that was also orally bioavailable in canines."( Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.
Do, ZN; Hammock, BD; Jones, PD; Morisseau, C; Tsai, HJ, 2006)		0.33
"05 nM) had excellent oral bioavailability (98%, n = 2) and blood area under the curve in dogs and was effective in vivo to treat hypotension in lipopolysaccharide challenged murine models."( Orally bioavailable potent soluble epoxide hydrolase inhibitors.
Hammock, BD; Hwang, SH; Liu, JY; Morisseau, C; Tsai, HJ, 2007)		0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bifunctional epoxide hydrolase 2Homo sapiens (human)IC50 (µMol)0.01400.00000.54509.1000AID1601280; AID1722863; AID1781044; AID1814168; AID1857694; AID270314; AID296663; AID568456; AID568458; AID638441
Bifunctional epoxide hydrolase 2Homo sapiens (human)Ki0.01950.00150.04540.1560AID1708974
Bifunctional epoxide hydrolase 2Mus musculus (house mouse)IC50 (µMol)0.00420.00170.05670.4220AID1601281; AID1781045; AID296658; AID568457
Bifunctional epoxide hydrolase 2Rattus norvegicus (Norway rat)IC50 (µMol)0.00600.00600.09800.3700AID296659
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
response to toxic substanceBifunctional epoxide hydrolase 2Homo sapiens (human)
positive regulation of gene expressionBifunctional epoxide hydrolase 2Homo sapiens (human)
dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
cholesterol homeostasisBifunctional epoxide hydrolase 2Homo sapiens (human)
stilbene catabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
phospholipid dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
regulation of cholesterol metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
magnesium ion bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide hydrolase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
toxic substance bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lipid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
protein homodimerization activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lysophosphatidic acid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomal matrixBifunctional epoxide hydrolase 2Homo sapiens (human)
cytosolBifunctional epoxide hydrolase 2Homo sapiens (human)
extracellular exosomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (69)

Assay IDTitleYearJournalArticle
AID568470Antihypertensive activity against spontaneously hypertensive rat assessed as decrease in mean blood pressure at 100 mg/kg, po2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID296661Inhibition of cat soluble epoxide hydrolase by radioactive assay2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Orally bioavailable potent soluble epoxide hydrolase inhibitors.
AID1722863Inhibition of recombinant human soluble epoxide hydrolase using CMNPC as substrate preincubated for 5 mins followed by substrate addition and measured at 30 secs interval for 10 mins by fluorescence assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors:
AID1186234Tmax in Swiss Webster mouse at 0.3 mg/kg, po administered as cassette dosing2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy.
AID1601282Microsomal stability in human microsomes assessed as parent compound remaining in presence of NADP, glucose-6-phosphate and glucose-6-phosphate dehydrogenase measured after 60 mins by UPLC-MS/MS analysis2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
AID568465Inhibition of CYP3A42011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID568466Membrane permeability across human Caco2 monolayer2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID1781084Reversible toxicity in ICR mouse assessed as eye secretion at 100 mg/kg, ip administered as single dose observed for 14 days2021European journal of medicinal chemistry, Nov-05, Volume: 223Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis.
AID296658Inhibition of mouse recombinant soluble epoxide hydrolase by fluorescent assay2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Orally bioavailable potent soluble epoxide hydrolase inhibitors.
AID568456Inhibition of human soluble epoxide hydrolase2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID1708975Binding affinity to purified recombinant human sEH assessed as residence time by FRET-displacement assay2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative.
AID568473Inhibition of soluble epoxide hydrolase in diet induced obese mouse assessed as inhibition of EET hydrolysis at 100 mg/kg, po BID for 4 weeks measured 7 hrs post last dose2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID296660Inhibition of hamster soluble epoxide hydrolase by radioactive assay2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Orally bioavailable potent soluble epoxide hydrolase inhibitors.
AID568460AUC (24 hrs) in rat at 10 mg/kg, po2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID568463Inhibition of CYP2C92011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID296659Inhibition of rat recombinant soluble epoxide hydrolase by fluorescent assay2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Orally bioavailable potent soluble epoxide hydrolase inhibitors.
AID676960Inhibition of sEH activity in human at 250 mg after 8 hrs2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.
AID1814170Metabolic stability in mouse liver recombinant microsomes assessed as parent compound remaining measured after 60 mins in presence of NADP by UPLC-MS/MS analysis2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
From the Design to the
AID1186232Cmax in Swiss Webster mouse at 0.3 mg/kg, po administered as cassette dosing2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy.
AID1708973Lipophilicity, logP of compound by HPLC analysis2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative.
AID1708972Solubility in 0.1M sodium phosphate buffer at pH 7.42021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative.
AID568464Inhibition of CYP2C192011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID676956Oral bioavailability in cynomolgus monkey2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.
AID1186238Inhibition of human CYP2C assessed as remaining activity at 10 uM2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy.
AID1857694Inhibition of human recombinant sEH2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain: A New Indication for Soluble Epoxide Hydrolase Inhibitors.
AID1186233Half life in Swiss Webster mouse at 0.3 mg/kg, po administered as cassette dosing2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy.
AID568461Inhibition of CYP1A22011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID1814169Metabolic stability in human liver recombinant microsomes assessed as parent compound remaining measured after 60 mins in presence of NADP by UPLC-MS/MS analysis2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
From the Design to the
AID568468Oral bioavailability in rat2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID1186231AUC in Swiss Webster mouse at 0.3 mg/kg, po administered as cassette dosing2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy.
AID676959Terminal half life in human2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.
AID676957Antidiabetic activity in DIO mouse assessed as inhibition of blood sEH activity at 100 mg/kg, po bid up to 7 hrs2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.
AID1186235Inhibition of human ERG expressed in HEK-293 cells at 50 uM by whole-cell patch-clamp technique2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy.
AID296664AUC in in dog at 0.3 mg/kg, po2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Orally bioavailable potent soluble epoxide hydrolase inhibitors.
AID676943Inhibition of sEH activity in human at 100 to 400 mg administered every 8 hrs2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.
AID568458Inhibition of soluble epoxide hydrolase in HUVEC assessed inhibition of as conversion of 14, 15-EET to 14, 15-DHET2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID568471Antidiabetic activity in diet induced obese mouse assessed as reduction in maximal glucose excursion at 100 mg/kg, po BID for 4 weeks2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID568457Inhibition of mouse soluble epoxide hydrolase2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID1781044Inhibition of human recombinant sEH using PHOME as substrate measured after 10 mins by fluorescent based assay2021European journal of medicinal chemistry, Nov-05, Volume: 223Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis.
AID1186230Inhibition of human recombinant soluble epoxide hydrolase assessed as half-life of enzyme-inhibitor complex by FRET-based ACPU displacement assay2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy.
AID1814168Inhibition of human recombinant sEH using CMNPC as substrate incubated for 5 mins by fluorescent based assay2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
From the Design to the
AID296662Inhibition of dog soluble epoxide hydrolase by radioactive assay2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Orally bioavailable potent soluble epoxide hydrolase inhibitors.
AID1186236Protein binding in human plasma at 1 uM2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy.
AID1722867Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Caco-2 cells at 10 uM measured after 2 hrs by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors:
AID1186237Inhibition of human CYP2J2 assessed as remaining activity at 10 uM2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy.
AID1781045Inhibition of mouse recombinant sEH using PHOME as substrate measured after 10 mins by fluorescent based assay2021European journal of medicinal chemistry, Nov-05, Volume: 223Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis.
AID1722865Apparent permeability across apical to basolateral side in human Caco-2 cells at 10 uM measured after 2 hrs by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors:
AID1601283Solubility of compound in 1% DMSO : 99% PBS buffer solution at 37 degree C measured after 2 hrs by nephelometer analysis2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
AID1722866Apparent permeability across basolateral to apical side in human Caco-2 cells at 10 uM measured after 2 hrs by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors:
AID270315AUC in dog at 0.3 mg/kg, po2006Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19
Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.
AID676958Antidiabetic activity in DIO mouse assessed as inhibition of blood sEH activity at 100 mg/kg, po bid after 12 hrs2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.
AID568474Antihypertensive activity against AngII-induced hypertension in telemetered rat assessed as decrease in systolic blood pressure at 50 mg/kg, po2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID270314Inhibition of soluble epoxide hydroxylase by kinetic fluorescent assay2006Bioorganic & medicinal chemistry letters, Oct-01, Volume: 16, Issue:19
Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase.
AID1601280Inhibition of recombinant human liver soluble epoxide hydrolase expressed in baculovirus infected Sf21 cells using NEPC as substrate by fluorescence based assay2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
AID676945Inhibition of human sEH by cell based assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.
AID638441Inhibition of human soluble epoxide hydrolase using CMNPC as substrate after 5 mins by fluorescent assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase.
AID1814171Metabolic stability in rat liver recombinant microsomes assessed as parent compound remaining measured after 60 mins in presence of NADP by UPLC-MS/MS analysis2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
From the Design to the
AID568467Oral bioavailability in cynomolgus monkey2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID568472Inhibition of soluble epoxide hydrolase in diet induced obese mouse assessed as inhibition of EET hydrolysis at 100 mg/kg, po BID for 4 weeks measured 12 hrs post last dose2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID568469Antihypertensive activity against spontaneously hypertensive rat assessed as decrease in mean blood pressure at 300 mg/kg, po2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID676961Inhibition of sEH activity in human at 500 mg after 12 hrs2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.
AID296663Inhibition of human sEH by fluorescent assay2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Orally bioavailable potent soluble epoxide hydrolase inhibitors.
AID1722864Solubility of the compound in 1% DMSO/99% PBS buffer solution measured after 2 hrs by light scattering based assay2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors:
AID568475Antihypertensive activity against AngII-induced hypertension in telemetered rat assessed as decrease in diastolic blood pressure at 50 mg/kg, po2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID1708974Binding affinity to purified recombinant human sEH by FRET-displacement assay2021Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative.
AID568459Inhibition of human ERG by patch clamp analysis2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID1601281Inhibition of murine soluble epoxide hydrolase expressed in baculovirus infected Sf21 cells using NEPC as substrate by fluorescence based assay2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
AID568462Inhibition of CYP2B62011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.
AID676955Oral bioavailability in rat2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (16.67)29.6817
2010's5 (41.67)24.3611
2020's5 (41.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.23 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.06 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1,3-dicyclohexylurea
1,3-dicyclohexylurea: degradation product of 1-(2-chloroethyl)-3- cyclohexyl-1-nitrosourea; structure		2.4620ureas
N-cycloheptyl-1-(4-methylphenyl)sulfonyl-4-piperidinecarboxamide
[no description available]		2.0710sulfonamide
4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid
[no description available]		3.2750
t-tucb
[no description available]		2.5820
thiouredopyrenetrisulfonate
N-[1-(methanesulfonyl)piperidin-4-yl]-N'-[4-(trifluoromethoxy)phenyl]urea : A phenylurea that is urea substituted by 1-(methylsulfonyl)piperidin-4-yl and 4-(trifluoromethoxy)phenyl groups at positions 1 and 3 respectively.		2.110phenylureasEC 3.3.2.10 (soluble epoxide hydrolase) inhibitor
au1235
[no description available]		2.9430
ConditionIndicatedRelationship StrengthStudiesTrials
Blood Pressure, Low
[description not available]		02.0310
Hypotension
Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.		02.0310
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.1140
Blood Pressure, High
[description not available]		02.4720
Insulin Sensitivity
[description not available]		02.0610
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		02.4720
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		02.0610
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		02.0610
Innate Inflammatory Response
[description not available]		02.5420
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.5420
Autoimmune Diabetes
[description not available]		02.110
Asymmetric Diabetic Proximal Motor Neuropathy
[description not available]		02.110
Nerve Pain
[description not available]		02.5720
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.		02.110
Diabetic Neuropathies
Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)		02.110
Neuralgia
Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.		02.5720
Acute Edematous Pancreatitis
[description not available]		02.6920
Acute Disease
Disease having a short and relatively severe course.		02.6920
Pancreatitis
INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.		02.6920
Blood Poisoning
[description not available]		02.3110
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		02.3110
Visceral Pain
Pain originating from internal organs (VISCERA) associated with autonomic phenomena (PALLOR; SWEATING; NAUSEA; and VOMITING). It often becomes a REFERRED PAIN.		02.4110